Synonyms: example 73 [WO2012068109A2]
Compound class:
Synthetic organic
Comment: ACY-738 is an orally-bioavailable histone deacetylase (HDAC) inhibitor [1-2]. It has some selectivity for HDAC6.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Cao Y, Ding Y, Liu Y, Mazitschek R, Van Duzer JH, Yu N. (2012)
Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof. Patent number: WO2012068109A2. Assignee: Acetylon Pharmaceuticals. Priority date: 16/11/2010. Publication date: 24/05/2012. |
2. Jochems J, Boulden J, Lee BG, Blendy JA, Jarpe M, Mazitschek R, Van Duzer JH, Jones S, Berton O. (2014)
Antidepressant-like properties of novel HDAC6-selective inhibitors with improved brain bioavailability. Neuropsychopharmacology, 39 (2): 389-400. [PMID:23954848] |
3. LoPresti P. (2019)
The Selective HDAC6 Inhibitor ACY-738 Impacts Memory and Disease Regulation in an Animal Model of Multiple Sclerosis. Front Neurol, 10: 519. [PMID:31316445] |